Becker Hewes

2.6k total citations · 2 hit papers
34 papers, 2.0k citations indexed

About

Becker Hewes is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Becker Hewes has authored 34 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 11 papers in Genetics. Recurrent topics in Becker Hewes's work include Advanced Breast Cancer Therapies (12 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Becker Hewes is often cited by papers focused on Advanced Breast Cancer Therapies (12 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Becker Hewes collaborates with scholars based in United States, Germany and France. Becker Hewes's co-authors include Viviana Cremasco, Sonia Quaratino, Britta Mueller, Philip J. Gotwals, Adam Crystal, Jeffrey A. Engelman, Catherine Sabatos-Peyton, Daniela Cipolletta, Scott B. Cameron and Glenn Dranoff and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Blood.

In The Last Decade

Becker Hewes

34 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prospects for combining targeted and conventional cancer therapy with immunotherapy

2017 766 citations Philip J. Gotwals, Scott B. Cameron et al. Nature reviews. Cancer profile →
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

2009 485 citations Raoul Herbrecht, Jorge Romaguera et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Becker Hewes United States	18	1000	624	617	457	393	34	2.0k
Thomas M. Cardillo United States	38	2.4k 2.4×	818 1.3×	1.3k 2.1×	256 0.6×	495 1.3×	94	4.1k
Maarten L. Janmaat Netherlands	17	1.3k 1.3×	567 0.9×	1.0k 1.7×	132 0.3×	525 1.3×	28	2.4k
Ben K. Seon United States	27	683 0.7×	642 1.0×	1.5k 2.5×	450 1.0×	267 0.7×	100	2.6k
Carla J. de Boer Netherlands	15	859 0.9×	432 0.7×	566 0.9×	241 0.5×	303 0.8×	19	1.8k
Serengulam V. Govindan United States	30	2.3k 2.3×	406 0.7×	905 1.5×	138 0.3×	656 1.7×	79	3.5k
Ningjing Lin China	15	609 0.6×	285 0.5×	457 0.7×	362 0.8×	128 0.3×	66	1.4k
Jamie Honeychurch United Kingdom	21	1.9k 1.9×	1.4k 2.2×	396 0.6×	333 0.7×	639 1.6×	53	2.9k
Ann Cleverly United States	25	1.5k 1.5×	530 0.8×	1.3k 2.1×	259 0.6×	333 0.8×	54	2.6k
Malin Pedersen United Kingdom	22	1.1k 1.1×	673 1.1×	1.3k 2.0×	130 0.3×	267 0.7×	37	2.4k
Emiliano Cocco United States	32	1.6k 1.6×	294 0.5×	1.1k 1.8×	169 0.4×	833 2.1×	83	3.2k

Countries citing papers authored by Becker Hewes

Since Specialization

Citations

This map shows the geographic impact of Becker Hewes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Becker Hewes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Becker Hewes more than expected).

Fields of papers citing papers by Becker Hewes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Becker Hewes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Becker Hewes. The network helps show where Becker Hewes may publish in the future.

Co-authorship network of co-authors of Becker Hewes

This figure shows the co-authorship network connecting the top 25 collaborators of Becker Hewes. A scholar is included among the top collaborators of Becker Hewes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Becker Hewes. Becker Hewes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Germa, Caroline, Michelle C. Miller, Pabak Mukhopadhyay, et al.. (2017). Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib. Annals of Oncology. 28(8). 2021–2024. 6 indexed citations

2.

Gotwals, Philip J., Scott B. Cameron, Daniela Cipolletta, et al.. (2017). Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nature reviews. Cancer. 17(5). 286–301. 766 indexed citations breakdown →

3.

Tolaney, SM, Valentina Boni, Thomas Bachelot, et al.. (2017). Abstract P4-22-12: Ribociclib + fulvestrant in postmenopausal women with HR+, HER2– advanced breast cancer (ABC). Cancer Research. 77(4_Supplement). P4–22. 4 indexed citations

4.

Knee, Deborah, Becker Hewes, & Jennifer L. Brogdon. (2016). Rationale for anti-GITR cancer immunotherapy. European Journal of Cancer. 67. 1–10. 165 indexed citations

5.

Juric, Dejan, Roohi Ismail‐Khan, Mario Campone, et al.. (2016). Abstract P3-14-01: Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis. Cancer Research. 76(4_Supplement). P3–14. 30 indexed citations

6.

Yamada, Yasuhide, et al.. (2015). Abstract B31: A Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors. Molecular Cancer Therapeutics. 14(12_Supplement_2). B31–B31. 7 indexed citations

7.

Juric, Dejan, Erika Hamilton, Laura García‐Estévez, et al.. (2015). Abstract P5-19-24: Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis. Cancer Research. 75(9_Supplement). P5–19. 15 indexed citations

8.

Münster, Pamela N., Erika Hamilton, Laura García‐Estévez, et al.. (2014). Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.. Journal of Clinical Oncology. 32(26_suppl). 143–143. 21 indexed citations

9.

Bardia, Aditya, Shanu Modi, Muaiad Kittaneh, et al.. (2014). Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.. Journal of Clinical Oncology. 32(15_suppl). 535–535. 19 indexed citations

10.

Münster, Pamela N., et al.. (2014). Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC).. Journal of Clinical Oncology. 32(15_suppl). 533–533. 28 indexed citations

11.

Hess, Gregory P., Jorge Romaguera, G. Verhoef, et al.. (2008). Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator’s choice therapy. Journal of Clinical Oncology. 26(15_suppl). 8513–8513. 23 indexed citations

12.

Gambacorti‐Passerini, Carlo, Hagop M. Kantarjian, Michele Baccarani, et al.. (2008). Activity and tolerance of bosutinib in patients with AP and BP CML and Ph+ ALL. Journal of Clinical Oncology. 26(15_suppl). 7049–7049. 11 indexed citations

13.

Hewes, Becker, et al.. (2007). T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity. Current Cancer Drug Targets. 7(1). 55–70. 27 indexed citations

14.

Cortes, Jörge E., Hagop M. Kantarjian, Gianantonio Rosti, et al.. (2007). Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).. Blood. 110(11). 733–733. 17 indexed citations

15.

Gambacorti‐Passerini, Carlo, Tim H. Brümmendorf, Hagop M. Kantarjian, et al.. (2007). Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib. Journal of Clinical Oncology. 25(18_suppl). 7006–7006. 17 indexed citations

16.

McMillin, Douglas W., Becker Hewes, Bagirath Gangadharan, et al.. (2006). Complete Regression of Large Solid Tumors Using Engineered Drug-Resistant Hematopoietic Cells and Anti-CD137 Immunotherapy. Human Gene Therapy. 17(8). 798–806. 14 indexed citations

17.

McMillin, Douglas W., Becker Hewes, Bagirath Gangadharan, et al.. (2006). Complete Regression of Large Solid Tumors Using Engineered Drug-Resistant Hematopoietic Cells and Anti-CD137 Immunotherapy. Human Gene Therapy. 0(0). 1527707827–1527707827. 1 indexed citations

18.

McMillin, Douglas W., Natalia Landázuri, Bagirath Gangadharan, et al.. (2005). Highly efficient transduction of repopulating bone marrow cells using rapidly concentrated polymer-complexed retrovirus. Biochemical and Biophysical Research Communications. 330(3). 768–775. 10 indexed citations

19.

Vargas, Roberto, et al.. (1996). Estradiol Effect on Rate of Proliferation of Rat Carotid Segments: Effect of Gender and Tamoxifen. Journal of Cardiovascular Pharmacology. 27(4). 495–499. 8 indexed citations

20.

Clauw, Daniel J., et al.. (1994). P-31 magnetic resonance spectroscopy of skeletal muscle in the eosinophilia-myalgia syndrome: a preliminary study.. PubMed. 21(4). 654–7. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact